Compare BGSI & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGSI | MRUS |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | Canada | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.1B |
| IPO Year | N/A | 2016 |
| Metric | BGSI | MRUS |
|---|---|---|
| Price | $169.38 | $96.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $94.94 |
| AVG Volume (30 Days) | 42.4K | ★ 1.3M |
| Earning Date | 11-12-2025 | 10-31-2025 |
| Dividend Yield | ★ 0.26% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $3,101,279,000.00 | $56,606,000.00 |
| Revenue This Year | $3.41 | $56.08 |
| Revenue Next Year | $9.32 | N/A |
| P/E Ratio | $292.50 | ★ N/A |
| Revenue Growth | 1.42 | ★ 57.54 |
| 52 Week Low | $136.81 | $33.19 |
| 52 Week High | $177.20 | $96.28 |
| Indicator | BGSI | MRUS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 69.98 |
| Support Level | N/A | $95.83 |
| Resistance Level | N/A | $96.19 |
| Average True Range (ATR) | 0.00 | 0.33 |
| MACD | 0.00 | -0.34 |
| Stochastic Oscillator | 0.00 | 68.46 |
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority, and Autoglassonly.com. In addition, the Company operates a third-party administrator, Gerber National Claims Services (GNCS), that offers glass, emergency roadside, and first notice of loss services.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.